Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
October 2013, Vol 4, No 8
October 2013, Vol 4, No 8
Kadcyla Prolongs Survival in Advanced HER2-Positive Breast Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—The antibody-conjugate ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, prolonged progression-free survival (PFS) in advanced HER2-positive breast cancer in a heavily pretreated population, according to the final results of the phase 3 clinical trial TH3RESA.
Read Article
The State of Cancer Globally in 2013
By
Audrey Andrews
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—Although much progress has been made in cancer care over the past couple of decades, a report presented at the 2013 European Cancer Congress emphasizes that on a global scale, the impact is far from equitable.
Read Article
New Approach to Treating Medulloblastoma Developed at NCI-Designated Cancer Center
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
A team of researchers at Sanford-Burnham Medical Research Institute, led by Robert Wechsler-Reya, PhD, Professor at Sanford-Burnham’s National Cancer Institute (NCI)-Designated Cancer Center and Director of the Tumor Initiation and Maintenance Program, discovered that they can block the rapid growth of cancerous brain cells by using small-molecule inhibitors.
Read Article
New Molecular Markers Can Identify Early Breast Cancer that Will Spread to the Brain
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
Researchers have identified new molecular markers—microribonucleic acids (RNAs)—that, combined with their target genes, are believed to be able to identify which breast cancer will metastasize to the brain.
Read Article
Mandate to Demonstrate Value in Cancer Care Is Growing: Oncologists Urged to Be Part of the Solution
Value Propositions
,
Value Peer-spectives
October 2013, Vol 4, No 8
The cost of cancer care has become a frequent topic of conversation in oncology conferences and publications, as well as among other stakeholders, including patients and payers. In a recent editorial published in the Journal of Clinical Oncology, David G. Pfister, MD, Chief, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, joined the discussion, acknowledging previous discussions related to the cost of cancer drugs and the notion that the status quo in drug pricing allows for arbitrary setting of a price for a drug that is not necessarily based on a demonstration of true value.
Read Article
Value-Based Care Will Change the Face of Medicine
Economics & Value
,
Value Propositions
,
Value-Based Care
,
Value Peer-spectives
October 2013, Vol 4, No 8
In a recent guest blog on the
Harvard Business Review
website, Toby Cosgrove, MD, President and CEO of the Cleveland Clinic in Ohio, suggested that value-based care represents a life-saving “breakthrough,” not unlike penicillin or decoding the human genome, by focusing on lowering costs and improving quality of care and outcomes as its main goals.
Read Article
Perjeta First Drug Ever Approved for Neoadjuvant Breast Cancer Therapy
FDA Approvals, News & Updates
October 2013, Vol 4, No 8
The US Food and Drug Administration (FDA) granted accelerated approval to pertuzumab (Perjeta; Genentech) as part of a treatment regimen for the neoadjuvant setting (ie, before surgery) for patients with HER2-positive early-stage breast cancer. This is the first time that the FDA approved a drug for the neoadjuvant treatment of patients with breast cancer.
Read Article
Is the US Cancer Care System in Crisis? The IOM Report
By
Craig Deligdish, MD
From the Editor
,
Value Peer-spectives
October 2013, Vol 4, No 8
On September 10, 2013, the Institute of Medicine (IOM), part of the National Academy of Sciences, published a 315-page report, titled “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis”.
Read Article
MPDL3280A: Responses Better in Smokers than in Nonsmokers in Advanced Lung Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—For the first time, a therapy for non–small-cell lung cancer (NSCLC) has achieved responses in smokers better than in nonsmokers. The antibody MPDL3280A also achieved good responses in squamous and adenoma histologic types of NSCLC.
Read Article
Growing Pressures on Oncolytics to Demonstrate Value
By
Caroline Helwick
October 2013, Vol 4, No 8
Hollywood, FL—Oncology growth for the next couple of years will be driven by several strong trends, according to Doug Long, Vice President of Industry Relations, IMS Health, who described these trends at the 3rd Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma